-
Benzinga's Bulls And Bears Of The Week: Amazon, Disney, Netflix And More
Saturday, May 30, 2020 - 1:47pm | 843Benzinga has examined the prospects for many investor favorite stocks over the past week. This week's bullish calls included e-commerce and pharmaceutical giants. The house that Warren Buffett built is featured among the bearish calls. The Dow Jones industrials and the S&P 500 ended last...
-
Notable Insider Buys: AbbVie, Bristol-Myers And More
Sunday, August 4, 2019 - 8:01am | 545Insider buying can be an encouraging signal for potential investors. Insiders were buying shares last week in the wake of earnings reports. Two big drugmakers saw sizable insider purchases in the past week. Conventional wisdom says that insiders and 10% owners really only buy shares of a company...
-
Bulls & Bears Of The Week: AT&T, Carnival, McDonald's, Microsoft And More
Saturday, June 29, 2019 - 10:51am | 890Benzinga has examined prospects for many investor favorite stocks over the past week. M&A candidates were among both the bullish and bearish calls last week. Top software stocks also saw both bullish and bearish calls. The big U.S. indexes ended the past week down marginally as investors...
-
Benzinga's Bulls & Bears Of The Week: Dropbox, GE, Microsoft, Twitter And More
Sunday, April 22, 2018 - 4:14pm | 766Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included big cloud plays, a leading retailer and a social media giant. Bearish calls included an electric vehicle leader, a struggling industrial giant and a big pharma. The broader equity...
-
Barron's Picks And Pans: Bristol-Myers, Texas Instruments, Altaba And More
Sunday, July 2, 2017 - 5:01pm | 602This weekend's Barron's offers a look at a big pharma stock that acts like a big tech one. Other featured articles discuss an old-school chip stock poised to reward investors and who the players may be in the coming surge in cable and wireless deal making. The prospects for an obscure aircraft...
-
Bristol-Myers Hit With A Trio Of Analyst Price Target Cuts
Tuesday, August 9, 2016 - 8:33am | 255Bristol-Myers Squibb Co (NYSE: BMY) saw its shares crater from near $75 last week to nearly $60 per share after the company reported a major setback for its cancer-treating drug, Opdivo. Bristol-Myers said Opdivo failed to meet a primary endpoint in the treatment of lung cancer during the...
-
Bristol Myers Ticks Higher Following Q4 Beat, Encouraging Guidance
Thursday, January 28, 2016 - 8:54am | 287Shares of Bristol-Myers Squibb Co (NYSE: BMY) were trading higher by around 1 percent early Thursday morning after the company released its fourth quarter results. Bristol Myers earned $0.38 per share in the fourth quarter on revenue of $4.3 billion. Wall Street analysts were expecting the...
-
Markets Little Changed Ahead Of 4th Of July Break
Wednesday, July 2, 2014 - 4:34pm | 2100U.S. stocks were little changed despite an ADP jobs report showing better-than-expected numbers. The ADP report comes ahead of the non-farm payrolls due on Thursday. Analysts are expecting the payrolls to confirm 212,000 jobs were added in June. The markets will close at 1:00 p.m. on Thursday...
-
Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss
Thursday, May 15, 2014 - 4:41pm | 2809U.S. stocks declined for the second straight day after investors and traders digested disappointing earnings from retailers and economic reports were disappointing. The Dow suffered a triple-digit point loss and declined one percent after the retailer giant Wal-Mart failed to "wow" investors....
-
Market Wrap For January 8: Fed Minutes Released
Wednesday, January 8, 2014 - 5:39pm | 2250Major indices finished Wednesday's trading session relatively flat as the Fed's minutes released had no impact on the markets. Minutes released from the Federal Reserve's latest meeting re-affirmed that many members on the committee wanted to proceed with caution in trimming the $85 billion...
-
Coverage Discontinued On ZymoGenetics
Thursday, October 14, 2010 - 7:32am | 88Piper Jaffray has published a report on ZymoGenetics, Inc. (NASDAQ: ZGEN) announcing that it has discontinued coverage as ZymoGenetics has been acquired by Bristol-Myers Squibb (NYSE: BMY), a deal that was completed yesterday. In the report, Piper Jaffray writes "Investors should no longer rely on...
-
PT Raised For BMY By Deutsche Bank
Wednesday, September 22, 2010 - 8:09am | 139Bristol-Myers Squibb Co. (NYSE: BMY) is having its price target raised to $31.50 from $28 by Deutsche Bank and reiterating its Buy rating, based upon “the prospects for important new drug catalysts by year end. [Our] price target is based upon a DCF valuation utilizing a 5.5 times terminal multiple...